Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data

Jasper Therapeutics, Inc.

Jeet Mahal named President and CEO to lead next phase of clinical growth.
Positive CSU data: 67% complete response in BEACON Cohort 9.1; 75% in open-label extension at 12 weeks.
Preliminary asthma data from ETESIAN study shows reduced airway hyperresponsiveness after single 180mg dose.
Internal investigation found no drug product issues; KOL panel recommends enhanced site selection and screening.
Q4 2025 net loss $9.1M; year net loss $75.8M; cash and equivalents $28.7M at Dec 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jasper Therapeutics, Inc. reported the quarter and year ended December 31, 2025 results: net income a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholder, EPS $0.32 and $3.95.

Period: the quarter and year ended December 31, 2025
Net income: a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholder
EPS: $0.32 and $3.95
Result: reported results

Exact text from the filing

Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended December 31, 2025, respectively.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-036448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.